Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

By Cremieux P-Y.  

PharmacoEconomics, Vol. 16, Iss. 5, 1999-11 ,pp. : 459-472

Adis International

Access to resources Recommend Favorite

Detection of Anti-Erythropoietin Antibodies in Haemodialysis Patients Treated with Recombinant Human-Erythropoietin

By Castelli G.   Famularo A.   Semino C.   Machi A.M.A.R.I.A.   Ceci A.   Cannella G.   Melioli G.  

Pharmacological Research, Vol. 41, Iss. 3, 2000-03 ,pp. : 313-318

Academic Press

Access to resources Recommend Favorite

Human Recombinant Erythropoietin in the Prevention and Treatment of Anemia of Prematurity

By Ohls R.K.  

Pediatric Drugs, Vol. 4, Iss. 2, 2002-01 ,pp. : 111-121

Adis International

Access to resources Recommend Favorite

Safe and efficacious use of recombinant human erythropoietin in malignancy

By Greaves Paul   Agrawal Samir  

Clinical Medicine, Vol. 7, Iss. 6, 2007-12 ,pp. : 617-620

Royal College Of Physicians

Access to resources Recommend Favorite

Biological and Biochemical Assays to Ensure the Quality and Safety of Plasma-Derived Products: Factor VIII Concentrates

By  

Current Pharmaceutical Analysis, Vol. 3, Iss. 2, 2007-05 ,pp. : 83-94

Bentham Science Publishers

Access to resources Recommend Favorite